

Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study

Hao Trong Nguyen · Nhi Thi Uyen Pham · Tu Nguyen Anh Tran · Nguyen Nhat Pham · Yen Thi Bui · Thao Thi Phuong Vu

Hao T. Nguyen

Ho Chi Minh City Hospital of Dermato-Venereology,
2 Nguyen Thong, Ward Vo Thi Sau, District 3,
Ho Chi Minh City, Vietnam

Nguyen N. Pham

Ho Chi Minh City Hospital of Dermato-Venereology,
2 Nguyen Thong, Ward Vo Thi Sau, District 3,
Ho Chi Minh City, Vietnam

Nhi T. U. Pham

Ho Chi Minh City Hospital of Dermato-Venereology,
2 Nguyen Thong, Ward Vo Thi Sau, District 3,
Ho Chi Minh City, Vietnam

Yen T. Bui

Novartis Vietnam Company Limited,
Ho Chi Minh City, 700000, Vietnam

Tu N. A. Tran

Ho Chi Minh City Hospital of Dermato-Venereology,
2 Nguyen Thong, Ward Vo Thi Sau, District 3,
Ho Chi Minh City, Vietnam

Thao T. P. Vu

Ho Chi Minh City Hospital of Dermato-Venereology,
2 Nguyen Thong, Ward Vo Thi Sau, District 3,
Ho Chi Minh City, Vietnam

Corresponding Author:	Hao T. Nguyen Ho Chi Minh City Hospital of Dermato- Venereology, 2 Nguyen Thong, Ward Vo Thi Sau, District 3, Ho Chi Minh City, Vietnam
Corresponding Author e-mail address:	nthao@ump.edu.vn

Supplementary table 1: Dropout rate of secukinumab treatment and reasons for drop-out at months 12, 24, 36, and 48.

	Month 12 (N = 232)	Month 24 (N = 90)	Month 36 (N = 59)	Month 48 (N = 25)
Drop-out rate, n (%)	35 (15.1)	32 (35.6)	16 (27.1)	8 (32.0)
Reasons for drop-out cases, n (%)				
Planning for a pregnancy	3 (8.6)	0 (0)	1 (6.2)	1 (12.5)
Switching to other agents or continued in another facility	4 (11.4)	4 (12.5)	1 (6.2)	0 (0)
Financial issues	5 (14.3)	12 (37.5)	3 (18.8)	2 (25.0)
Adverse events	1 (2.9)	0 (0)	0 (0)	0 (0)
Do not achieve the as-expected efficacy	2 (5.7)	3 (9.4)	0 (0)	1 (12.5)
Unknown causes/loss of follow-up	20 (57.1)	13 (40.6)	11 (68.8)	4 (50.0)

Supplementary Table 2: The relationship between the patients' characteristics and the adherence to secukinumab over time







	Month 12			Month 24			Month 36			Month 48		
	Adhered	Dropped	<i>P</i>	Adhered	Dropped	<i>P</i>	Adhered	Dropped	<i>P</i>	Adhered	Dropped	<i>p</i>
Age group			1.000 ^a			0.327 ^a			1.000 ^a			0.595 ^a
≤ 65	187	34		118	62		55	48		11	23	
> 65	10	1		5	5		3	3		2	2	
Sex			0.007^b			0.155 ^b			0.494 ^b			1.000 ^a
Male	141	17	RR = 1.18	86	40		40	32		10	18	
Female	56	18	(1.03;1.36)	37	27		18	19		3	7	
Biologic state			0.220 ^a			0.522 ^a			1.000 ^a			0.595 ^a
Non-naïve	8	3		6	5		4	4		2	2	
Naïve	189	32		117	62		54	47		11	23	
DMARDs state			0.379 ^a			0.499 ^a			1.000 ^a			0.265 ^a
Non-naïve	11	0		8	2		3	2		2	1	
Naïve	186	35		115	65		55	49		11	24	
Concomitant PsO therapy			0.016^b			0.006^b			0.044^b			0.301 ^a
With	88	8	RR=1.14	58	18	RR=1.34	28	15	RR=1.43	6	7	
Without	109	27	(1.03;1.27)	65	49	(1.09;1.64)	30	36	(1.02;2.02)	7	18	
Medical insurance			<0.001^b			<0.001^b			<0.001^b			0.004^b
With	171	20	RR=1.41	113	41	RR=2.64	53	21	RR=5.01	11	9	RR=4.95
Without	26	15	(1,11;1,79)	10	26	(1,55;4,51)	5	30	(2,20;11,43)	2	16	(1,26;19,39)

^a*P* values from the Fisher exact test.

^b*P* values from the Chi-squared test.

DMARD, disease-modifying antirheumatic drug; PsO, psoriasis; RR, relative risk.

Supplementary Figure: Kaplan-Meier plots of secukinumab drug survival over 48 months in terms of (A) age group, (B) sex, (C) biologics-naïve state, (D) DMARDs-naïve state, (E) concomitant PsO treatment, and (F) medical insurance. The p-values are from log-rank test



DMARD, disease-modifying antirheumatic drug; PsO, psoriasis